发明名称 Quinolone compound and pharmaceutical composition
摘要 The present invention provides a quinolone compound represented by General Formula (1); or a salt thereof, wherein R1 represents a hydrogen atom, etc.; R2 represents a hydrogen atom, etc.; R3 represents a phenyl group optionally being substituted with one or more substituents, etc.; R4 represents a halogen atom; R5 represents a hydrogen atom or halogen atom; R6 represents a hydrogen atom; and R7 represents a hydroxyl group, etc. The quinolone compound have a functional improvement effect, which suppresses progression of neurological dysfunction by inhibiting the chronic progression of Parkinson's disease or protecting dopamine neurons from the disease etiology, thereby prolonging the period before first administration begins.
申请公布号 US9045464(B2) 申请公布日期 2015.06.02
申请号 US201414147115 申请日期 2014.01.03
申请人 OTSUKA PHARMACEUTICAL CO., LTD. 发明人 Otsubo Kenji;Ochi Yuji;Nakai Masami;Mori Atsushi
分类号 A61K31/04;C07D413/04;C07D215/233;C07D407/04;C07D409/04;C07D401/04;C07D405/04 主分类号 A61K31/04
代理机构 Sughrue Mion, PLLC 代理人 Sughrue Mion, PLLC
主权项 1. A method for treating Parkinson's disease, comprising administering a quinolone compound of General Formula (1) or a salt thereof to a human or an animal: wherein R1 represents a hydrogen atom, a lower alkyl group, a cyclo C3-8 alkyl lower alkyl group, or a lower alkoxy lower alkyl group; R2 represents a hydrogen atom, a lower alkyl group, or a halogen-substituted lower alkyl group; R3 represents a phenyl group, a furyl group, a thienyl group, or a pyridyl group, each of the groups optionally being substituted with one or more groups selected from the group consisting of the following (1) to (16) on the aromatic or heterocyclic ring represented by the above R3: (1) lower alkyl groups, (2) lower alkoxy groups, (3) halogen-substituted lower alkoxy groups, (4) a phenoxy group, (5) lower alkylthio groups, (6) a hydroxy group, (7) hydroxy lower alkyl groups, (8) halogen atoms, (9) lower alkanoyl groups, (10) lower alkoxycarbonyl groups, (11) amino groups optionally substituted with one or more lower alkyl groups, (12) carbamoyl groups optionally substituted with one or more lower alkyl groups, (13) cyclo C3-8 alkyl lower alkoxy groups, (14) pyrrolidinyl carbonyl groups, (15) morpholinyl carbonyl groups, and (16) a carboxyl group; R4 represents a halogen atom;R5 represents a hydrogen atom or a halogen atom;R6 represents a hydrogen atom; andR7 represents any one of groups (1) to (15) below; (1) a hydroxy group, (2) a halogen atom, (3) a lower alkoxy group, (4) a halogen-substituted lower alkoxy group, (5) a hydroxy lower alkoxy group, (6) a lower alkoxy lower alkoxy group, (7) an amino group optionally substituted with one or more members selected from the group consisting of lower alkyl groups, lower alkoxy lower alkyl groups, and cyclo C3-8 alkyl groups, (8) an amino lower alkoxy group optionally substituted on the amino group with one or more members selected from the group consisting of lower alkyl groups, lower alkanoyl groups, lower alkyl sulfonyl groups, and carbamoyl groups optionally substituted with one or more lower alkyl groups, (9) a cyclo C3-8 alkyloxy group, (10) a cyclo C3-8 alkyl lower alkoxy group, (11) a tetrahydrofuryl lower alkoxy group, (12) a lower alkylthio group, (13) a heterocyclic group selected from the group consisting of morpholinyl groups, pyrrolidinyl groups, furyl groups, thienyl groups, and benzothienyl groups, (14) a phenyl lower alkoxy lower alkoxy group, and (15) a pyrrolidinyl carbonyl group.
地址 Tokyo JP